Risankizumab is a recombinant humanized IgG1 monoclonal antibody and a selective interleukin-23 (IL-23) inhibitor. It specifically binds to the p19 subunit of human IL-23 and prevents its interaction with the IL-23 receptor. Risankizumab is the active pharmaceutical ingredient in SKYRIZI and is an important biologic API for pharmaceutical development and manufacturing.
Risankizumab is manufactured using recombinant DNA technology in Chinese hamster ovary (CHO) cells. FDA describes risankizumab-rzaa as a humanized IgG1 monoclonal antibody with an approximate molecular weight of 149 kDa.
Risankizumab API is a complex biological pharmaceutical ingredient designed to selectively target the IL-23 pathway. It is also known by development names BI 655066 and ABBV-066, with CAS No. 1612838-76-2. FDA identifies risankizumab-rzaa under this CAS number and FDA UNII 90ZX3Q3FR7.
Unlike conventional small-molecule APIs, Risankizumab is a large protein molecule whose quality depends on molecular identity, higher-order structure, glycosylation, purity, aggregation, charge heterogeneity and biological activity. Therefore, its characterization requires specialized biopharmaceutical analytical methods rather than conventional small-molecule API testing.
Risankizumab is a humanized IgG1 monoclonal antibody consisting of two heterodimers, each containing a heavy and light chain. The heavy chain contains 449 amino acids and the light chain contains 214 amino acids. The molecule has been engineered with Fc-region mutations to reduce potential effector-function activity.
Risankizumab selectively recognizes the p19 subunit of IL-23 without binding to IL-12. By inhibiting IL-23 signaling, it reduces downstream inflammatory signaling and the release of pro-inflammatory cytokines and chemokines.
Its biological nature means that conventional parameters such as melting point, residue on ignition and small-molecule HPLC assay are not appropriate primary release characteristics for the intact biologic API.
Risankizumab API is used in the development and manufacture of biologic medicines for inflammatory and immune-mediated diseases.
Current European regulatory information identifies Risankizumab-containing Skyrizi for several therapeutic applications, including:
The medicine is used to reduce inflammation associated with these IL-23-mediated conditions.
The selective IL-23 p19 mechanism makes Risankizumab an important biologic API for modern immunology and inflammatory-disease pharmaceutical development.
Quality control of Risankizumab requires biologic-specific analytical testing to establish identity, purity, molecular integrity and biological activity.
Regulatory assessment documents describe analytical controls including:
EMA assessment documentation specifically describes peptide mapping, cation-exchange chromatography, size-exclusion chromatography, capillary gel electrophoresis and reporter-gene bioassay as part of the quality-control strategy for Risankizumab-containing products.
Because Risankizumab is a biological monoclonal antibody, numerical specifications for conventional small-molecule parameters should not be invented or transferred from unrelated APIs.
Risankizumab is a sophisticated recombinant monoclonal antibody API requiring controlled cell-culture manufacturing, purification and extensive characterization.
A pharmaceutical-grade Risankizumab manufacturing program should emphasize:
These controls are particularly important for maintaining the consistency and biological activity of a monoclonal-antibody API.
Risankizumab API or drug substance should be stored in validated pharmaceutical containers under controlled conditions appropriate for a recombinant monoclonal antibody.
The marketed Risankizumab drug product is stored under refrigerated conditions, and the finished product should be protected from light and should not be frozen. API/drug-substance storage conditions should be based on the validated stability program and applicable manufacturer specification rather than automatically applying finished-product conditions.
Research-grade Risankizumab materials may have different storage requirements depending on formulation and concentration, so the applicable batch documentation should be followed.
Risankizumab API documentation may include:
Risankizumab is an established IL-23-targeting monoclonal antibody with broad pharmaceutical applications in inflammatory and immune-mediated diseases. Its selective mechanism, established clinical use and extensive regulatory characterization make it an important biologic API for pharmaceutical development.
A quality-focused Risankizumab API program should provide:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |